TW219933B - - Google Patents
Download PDFInfo
- Publication number
- TW219933B TW219933B TW079105258A TW79105258A TW219933B TW 219933 B TW219933 B TW 219933B TW 079105258 A TW079105258 A TW 079105258A TW 79105258 A TW79105258 A TW 79105258A TW 219933 B TW219933 B TW 219933B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- propyl
- item
- binding
- urine
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 23
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 36
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 241000283073 Equus caballus Species 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 12
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 11
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 6
- -1 propyl- Chemical group 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- 229940116269 uric acid Drugs 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 244000166124 Eucalyptus globulus Species 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012452 mother liquor Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 241001674048 Phthiraptera Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims 6
- 238000012360 testing method Methods 0.000 claims 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 3
- 210000001320 hippocampus Anatomy 0.000 claims 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 241000257465 Echinoidea Species 0.000 claims 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000006274 endogenous ligand Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000005065 mining Methods 0.000 claims 1
- 238000002715 modification method Methods 0.000 claims 1
- KYRWFMNSRMMWKE-UHFFFAOYSA-N n-benzyl-n-methylpropan-1-amine Chemical compound CCCN(C)CC1=CC=CC=C1 KYRWFMNSRMMWKE-UHFFFAOYSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000013222 sprague-dawley male rat Methods 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- YTOJFUORFUYGSV-UHFFFAOYSA-N 4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboxamide Chemical compound C1=C(C(N)=O)C(CC(N(CCC)CCC)C2)=C3C2=CNC3=C1 YTOJFUORFUYGSV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000007968 uric acids Chemical class 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 240000007591 Tilia tomentosa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- HQDYNFWTFJFEPR-UHFFFAOYSA-N 1,2,3,3a-tetrahydropyrene Chemical compound C1=C2CCCC(C=C3)C2=C2C3=CC=CC2=C1 HQDYNFWTFJFEPR-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFOTYEPBHMZLQW-UHFFFAOYSA-N FC=1C(=C(C2=CC=C3C=CC=C4C=CC1C2=C43)F)F Chemical compound FC=1C(=C(C2=CC=C3C=CC=C4C=CC1C2=C43)F)F LFOTYEPBHMZLQW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001254607 Leander Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000871457 Mauria Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- NASRDENTZCCAPN-UHFFFAOYSA-N OC([Na])=O Chemical compound OC([Na])=O NASRDENTZCCAPN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241001379934 Rumai Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VYVWGFNMEOCPBZ-UHFFFAOYSA-N [O][Kr] Chemical compound [O][Kr] VYVWGFNMEOCPBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- ISQINHMJILFLAQ-UHFFFAOYSA-N argon hydrofluoride Chemical compound F.[Ar] ISQINHMJILFLAQ-UHFFFAOYSA-N 0.000 description 1
- WOMUXWWKRWRGIP-UHFFFAOYSA-N argon propan-2-one Chemical compound [Ar].CC(C)=O WOMUXWWKRWRGIP-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical group N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FFDKYFGBIQQMSR-UHFFFAOYSA-N n-propyl isocyanide Chemical compound CCC[N+]#[C-] FFDKYFGBIQQMSR-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- SIWVEOZUMHYXCS-UHFFFAOYSA-N oxo(oxoyttriooxy)yttrium Chemical class O=[Y]O[Y]=O SIWVEOZUMHYXCS-UHFFFAOYSA-N 0.000 description 1
- VTRUBDSFZJNXHI-UHFFFAOYSA-N oxoantimony Chemical compound [Sb]=O VTRUBDSFZJNXHI-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
219933 經濟部中央橾準局印裂 五、發叼説明(1 , 本發明係關於製票化学之領 「 崎且包含經取代四氣采子 c d «引嘴之結晶迄及其用途。 祸拉C Flaugh )於美國專利 _ 甲请案第4576959號中揭 不6'經取代'4〜二烷基胺基揭 Ti ^ Λ 四丞•笨幵[c’dj吲— -製蔡上合格堪為中椎色洛,窄畤》广、上政4· 女争(Serotonin )作用旁笮效用在治療抑费、肥胖、酒 j? 稍'中毒、抽煙、或老年袭” 〇林登(Leander )於美 步揭示特定卜二w、/1案弟4745126號中進- ,……〔:”二喻―1,3’2 塩,具可笮效及其製藉上合格酵添加J …,效地治療焦慮。技藝中已確認若固體製票物 ),則特別賓優‘f, …、、”日升K而不爲朴晶奇 有特點,且較非、, ’結晶®體較易純化,幻 且敉扑抑形固體在妒桀 拉及林登所揭示之 鯈。本發明提供較福 例π之#佳化合物之 〇叫喊加成塩。 本發明提供4 一 ~1,3,4 5 一正―丙基)胺基〜6、胺基棘基 ,5~四氬笨秤〔c Η ,,, 另一具ϋ説明貢例中, ,11哚馬尿酸。於 形劑、稀释削 包括含該化合物連同製票赋 説明賞例關於上f物配方。本發明-另-具體 以‘〇療拉中需改良 龙文級化合物 明另一具浐〜 备妥年功&疋哺乳動物之.、t . ^ n 具植巩明货例aa、 '万法。本發 事、抑# > & $ H闞於治療人類抑辨之方 心抑费之病患該化么 々去,包含投與 勺日H I , 口物 < 抗抑鬱劑量〇本發明 说明貫例關於治疹 本發明之另一具體 ___ 已令技與易戚受焦慮 肀 4(210X297 乂发) 一請先閱讀背面之注意事項再琪寫本百) -¾. 4 3 - 219933 A6
(請先ΚΙ讀背面之注意事項存填寫本1) .装. •打· 219933 五、發明說明;3 , 馬展駿壤。該 不像多種其 承敵造具特別 僙高纯度馬尿 溶劑或情性溶 之堪結晶。所 者發生化學性 好溶劑亦具低 丙蟇醇輿水之 甲替甲醯胺、 溶劑包括異丙 凊需要,可藉 純化產物。捵 結晶作用,振 之結晶作用步 之母液可再循 吾人發現馬 現水與特定其 ,為儘#滅少 劑中爲較佳〇 用至少約5容 佳,以至少約 餡需要加熱溶 製備纯度超過 塩 相 當 於 吲 哚 對 馬 來 他 己 製 備 之 式 I 添 優 良 之 結 晶 >\± 〇 以 結 酸 塩 f 其 係 藉 溶 解 m 混 合 物 中 添 加 馬 選 溶 % 溶 解 馬 尿 反 β 〇 溶 劑 對 馬 尿 辭 毒 〇 溶 劑 包 括 異 丙 混 合 物 甲 基 基 酮 已 腈 及 異 丙 基 醇 輿 醋 基 醇 異 丙 基 與 水 一 次 ή 多 次 從 該 溶 劑 之 « % ·丨丨、 溶 fi'i C 如 著 使 用 第 溶 劑 ( 如 脉 〇 若 有 需 要 9 從 該 環 而 充 作 溶 劑 以 溶 解 屎 駿 塩 -¾ 明 顯 有 溶 他 溶 劑 比 較 明 m 優 保 有 其 他 溶 劑 9 當 例 如 當 採 用 矣 丙 基 醇 積 水 百 分 半 爲 較 佳 9 15. 容 水 百 分 孕 爲 曰 M. 劑 以 僮 TSJ 增 大 塩 之 溶 99. % 之 塩 〇 朴 結 晶 之 A6 B6 醚莫耳比為1對1 〇 加塩,式I化合物之馬 晶物質而言,可輕易製 化合物(4丨嗓)於情性 尿酿,然後將如此形成 酸及吲哚,但不應與兩 堪if Μ具低溶解度。最 蟇解、丙綱、I醇、異 、丁醇、四氬吱喃、二 敢I»暗之混合物。較佳 之混合物、及I醇。若 中再結晶產物而進—夕 異丙基醇)可用在第一 I醇)於至少一個隨後 隨後結晶作用步騄而來 馬展駿。 爲1〗於結晶晶格中,亦發 先保留於晶格中0因此 可共容時以將水加至溶 充作最初溶劑時,以使 以10.谷積水百分率爲更 佳。如一般之情況,可 離。藉結晶作用可因此 其他塩形式不能輕易纯 〔c d j吲哚對掌护$可邁擇性地涵导 219933 五、發明.說明ί 4 化,且常常需採用昂 Ρ货、冗長之色層分析技衡作純化。 有機及製喿化学宏趾汝、、 册確認式I化合物之馬尿联塩含一個 姆掌性破中心。本發 月化合物不論是否其货質上以R對掌 物存在,贯質上以s 了旱物存在,或以兩種對掌物混合物 存在,均屬有用。魃仕m 絲佳具髖説明賞例畚式I化合物之馬尿 賤兹貫货上矣·.此尉堂札 4 __ 物’尤其是R對掌物較佳。若欲製備 4 (--正-丙基)胺基_6一胺基敉基_】,3 , 4 ’ 5四u开〔e d〕㈣馬尿酸摄之外消旋混合物, 則鹼化合物可籍前一
迷福拉所揭示之方法製備。尤其,下述 方法可用以製備故^ A t 〇物之單一對掌物,然後可用以製備 馬尿酸兹之36- —·對掌物 下述1~笨傾一] ' ,5_環氧基~1,2,2压,3, 4 , 5 —六查策并
絶…,,第 30.紇,第 3935 _ 3938 C 1989 )頁中揭示之方法製備: (請先閱讀计面之注意事項再填寫本页) i. ,打· 經濟部中央橾準局印裝
III ο
冚b之〇消旋混合物與含對掌秩中心之—級除(如 爹·基匕基按·)反應產製下式之(dias1:ere〇mers ) 甲 4(210X 297 公寒) 6 219933 五、發明説叼:f 菲對掌物對:
IV
CsH5 9«^5
經 濟 部 中 央 抹 準 局 印 製 胖對掌異構物可藥常用 •用在技藝中之各教方法c如色層分 析fer及泛:择性結晶作萍丨)而+ ” 作用)向予以分離。於單一步騄中製備 式*ιν·貫質上純钟詞'裳复禮如* R 子矣構物芡具特笮優勒之方法如下述 。反應於一正一丁醇中約Μ下(濃度為每9毫升落劑約i 克⑽物)迄行歷約,.小時。於冷…陶,式 ivb之朴對掌異構物保留於 攸中,而式}y\之补對掌異構 物可形成結晶,且可鉍過濾收集。 爲氣化討論*示於-p分士,玄 ' 後取中間髖及.產物為由式IV · 化合物所產生之化合物。當 • &进、使用一笨基I基Si 代普上述反爲之S~i—采1 冬卷匕基te妍農生式奴·貌像化 合物之迤择性結晶作用,且 关使用在叕合成中產生示於T 文之對掌物之後繼中間體.及*知 炫及產物0除1~笨基C基桉外, 其他旋光活性~鈒胺亦可使月。 製備本發明化合物較佳起始物贫之下—步為形成式 氬丙咬。 甲 4 (210X297 公考) {請先Μ讀卄面之注意事項再填寫本頁) .笟· k. 213933
A B 五、發明説明(l C6Hs
V 若千從貝他胺基醇形成良丙啶之方法爲技蜃中巳知。較佳 方法爲於二氣甲炫中将式]V·化合物與三c蟇胺5甲烷磺 醢氣反F。下列化合物可從反應溶液中離析:
C
V a 經 濟 部 中 央 揉 準 局 印 装 式V之氣丙咬經f金屬催化劑C如鈀〕而氬解 '重要拓 是良丙啶之開垠以形成二級胺賁贺上為位置特具性( 免丙< 需開環以形成货質上4 -解 基化合物,該方%之^! ‘ y & 土, Λ 疋如Υ.蘇奇(Sugi )及S .米特蘇( Mitsui ),日本化學協舍奋也.^ --貧曰 43. » ^ 1489 - 1496 ( 1970 )所敎導之催化扣 乙拴虱知作用。較佳溶劑為醋歃與甲 醇之混合物,且反j於 ,^ :約一大乳壓氩氣下使用贵金馬當 化舞厂C最好為把)進杆& 仃0於〜5 *C下挽拌反應混合物庄^ ....................................................................................’::.........................練 t請先閲讀背面之注意事項再填寫本頁)
219933 五、發明説明(7 , 氣丙啶消耗爲止,其可藉埠層多 唷色層分析法或液相色層分杯 法予以測定。該氩解作用之產 听 產物菸一級胺,1一篆甲驗1 — CS — 1—笨暴L基;)脸 * J - 1 ,2 ,2a ,3 4 ,5 -六氟笨幷〔c , d j吲必•甘 I. * J吲嗦,其不需離析。水 用於約1大氣壓氩氟及約55 V α Ύ •C下進打,疽至二級胺消 止,其可授髂層色層分析法或遍扣Α & 馬 歲液相色層分析法予以蜊定。 離析,如藉結晶作用,可提件弋 &供式.巩貫質上對掌性純化合物 ’其 ·
C
VI 式VJi化合物可於在溶劑C如乙腈)中之鯰c如藏酸鉀) 存在下以式YI化合物與丙基峡行炫化作用,接著於溶劍( 如睹酸溶液)中之酸.c如破较或三氟睹奴)存在下藉換及 原高轵駿行碘化反應而槳備。碘化作用亦可在炫化作用之 前0
Ν /諫先«5續背面<>±意事!?再填寫本頁} t τ 經濟部中央櫺準局印奴
9 甲 4(210X 297公廣) 9933
Of {
發叼說B月, 下述式I化合
Ν (η〇3Η7)2 la 經 濟 部 央 抹 準 局 印 裝 可於催化劑〔最好 , ^ 、好矣鈀催化劑,如雙f三笨蟇_)钯氣或 戈C二苯基峨·)纪:里.Ί * ’ ‘、·〕存在下以式\ί1化合物與一氧化狭及 氣約等莫耳混a π r 0物反#而製備。催化劑最好以約每其耳反 I基赏0.05莫耳之比年存&。較#溶劑為甲篆,且反應 1濃度矣每1〇 〇毫升溶劑約〇 · 5至约2。〇克較佳。將反應 ” °•封歲之後’於約i〇〇 „c下扰拌反應混合物歷約6小時 ^ 一氧化歡反中权用之此釔傕化轺由史 椒化學細誌,主,笫3325 C 1974 ) 巴特雷提及海克於笮尥化睪錐誌,39.弟 頁揭示。笨辛龌基囷隨後可以技餐中已知 多a方法之任一種予以移除,但最好於新鲜蒸麴四私呔嗦 中與約4等價i〜丁基錤反應。去保鼉作用反應於約—讯· 下進行。反鹿藉添加I : ;!(:容積:容積)之水與四氪呔 噍而騄冷,而所產生4 一(二—主一丙基)胺基—6 一按 基被基~1 ,2 ,2 a ,3-,4 ,5~六氣茱丹.〔,c、d 〕吲嗦係箱蒸發四氬呋喃、從水相羊取進入容動c如亞甲 基氣)且矣發溶劑而離析。籍福拉於.矣國專利案第沾76959 號所揭示於醋駿中與二私化&L反應或於▼醇中於狭上纪反 。仏芳έ.鹵化 考柏格及海克 頁與史考柏格 3318 C 1974 甲 4(210X297 公簷) 10. 一 ί請先閑讀计面之:沈意事項再填寫本頁) 經 濟 部 中 央 搮 準 局 印 219933 五'纶明說明ί 9 , 應而氧化六氬笨井一〔c ,d〕 〜 尽 」吲哚之万法可得到所欲4 二一正一丙基)胺基-6〜按基椒基_【,3 , 4 5 ~四氮笨幷〔c ,d J吲哚。 ’ ’ 4~C二-正—丙蟇:)胺基〜6〜胺基禕基叫 3 4,5 一…捋〔C,…丨咳馬尿酸垣之製備如上丄 所边’其藉溶解式I鹼化合物於惰 情乜落劑中,然後再與約 1或更多等價馬朱献接觸而完成。 ★接觸作用可於溫度約0 C至約1 00 t下,最好從約〇 v 一 ^ υ C至約25. 下進行。適A ! 劑包括上文所討論之溶劑。 α ' 下述貫例提供用以説明本發 + «叨,但亚不以限制本發 圍爲目的。 货例1 骑馬尿酸".60克,3.3毫莫耳)與丙酮( /ii ^ Ο 疋後,加熱至45.°c溶解馬尿蚁。將溶解於丙酬(10 ml )中之 CR)-4_f- χτ π. 、 V--ϋ ~丙蟇)胺基—6 ~按基概 ,3 ,4 ,5~四氩笨丹—〔c , d〕吲吟(I·。 3。3毛莫耳)逐滴添加至必c馬尿駿溶液中。於免氣 下伴隨挽拌冷却混合物。25. „c下犯分錢後,添加少於1毫 克〈種抑。1分鐘以內溶液變混濁,1結晶開始形成,掉 落至燒瓶底部。挽拌 什'昆合物30.分鐘之後,尤許餑置1小時 〇過液混合物,乳以 51'劑級丙酮洗滌固髖0藉氣流乾燥固 體之後*於真空下齡, 、 乳%以獲得1.32无白色固體0分析固 髖可得下述結果。 熔點:19 2 ~ U4。(: 〇 ?4(210X 297^¾)
ί請先閑讀背面之注意事項再填寫本頁) .襄· ο 19933 A 6______Β6 五、發明説明(10., UV ( 醇〕: 240ηα (ε = 42,000), 281nm (ε = 5650) IR (KBr): 3141, 3135, 1653, 1603, 1578, 1544, 1384, 1367> 1357, 1279, 1254 [a]D = 甲醇〕 MS: m/e = 300, 180 分-析:(c27h34o4n4n論值贫.除值 C Η Ν 67-76 7*16 11.71 67.59 6.93 11-43 x 光結晶学提供晶胞大小,以A表示: 經濟部中央搮準局印裂
of·· a = 10.2974(5); b = 12.0619(3); 20.1382(6). 與 or = 90。,β := 90。,6 = 90。 容積=2501.29 ± 1.45 ρ 貫例2 将2.70克(is.毫莫耳)馬尿酸添加至4〇mI異丙基醇中 加热混合彳;.至7a °c以溶·解馬尿酸。於热落液中,添加溶 於尨毫升異丙基蜉中約4.5克C 14.9毫莫耳)(S ) — ( 丙基〕胺基~ 6 ~胺基和'基一 1 ,3 , 4 5四也笨并L c » d 便溶液冷却至J:溫,30L 分鐘後曰色結晶形成。柷拌混合物歷2小時之後尤許隔夜 #置。適濾混合物,且塊狀物以異丙基稃洗滌。於40L.C下 乾操塊狀物歷5小時以產生5 5克固後。箱NMR發現固燈 含約3重量百分年異丙基稃。浪缩通液扨成泡沫,以故溶 液/ 一氣甲炫藏合物羊取,真空下乾燥歷24.小時。 於C下銜5.4克固鉍溶於私毫升之異丙基醇與水(9Q • 1(X,V . V)之混合物甲。伴隨杬拌使溶液冷却至苏。c °刮堍瓶且添加已溶解固S材料之穠晶。放置溶液於5 -C
甲 4(210X297公 ί請先閲讀背面之注意事項再填寫本頁) .装· .線. 219933 經濟部中央棣準局印製 A6 B6 五、發明説叼..u.; 之冷柬器中;1小時後結晶形成。刮燒瓶可致更多結晶形 成 °混 合物於5 °C下 隔夜貯存 9 並 予以 過濾。以異 丙基路 洗 滌固 體,ϋ 於 50. X: 下真空乾 燥 歷 24.小 時以提供3 . 78克 白 色固 體。分析白色 固體提供 下 述 數據 • 熔 點: 190.5-192°C IR (KBr): 3458, 3134, 2975, 1655, 1604,: 1545, 1384, 1278 cnT1. ία UV ]D= (L· +39.4° (c = 0.1, ψ -轉.):278nm (ε = 4880), m ) 240nm (ε =44000) 柝 (C27H34N404) 理 論值 C 67.76 Η 7· 16 N 11.71 Τ f祭值 68.24 7. 46 11.40 货 例3 CRS) — 4-C 二 ~丟__ 丙卷〕 丨胳基—6 —膝基祿基 1 , 3 , 4 , 5 — 四氩篆井 c C ,d 〕吲嗦馬尿 酸塩之 外 消旋 混合物佔藉混 合等1之 極 純 對缺 體吲嗦馬尿 酸塩而 製 備° 将150毫克C R )〜4 一 C 一 正一丙基) 胺基— 6 ~ Me 基赛基一 1 3,4, 5 — 四氫 笨并C C d :)吲 l馬摩 -騃圾與150毫 :克相當之 C S )- 吲嗦馬尿礙 :埴合倂 〇 册混 合扨灌入10.毫 升之0。2 當 量 HC1 。将10.毫升 醋駿1 蠍 加入 •接著加入10. 毫升'之5 當 取氧 化納。分離 水層及 有 概層 ,且以10.毫升 醋駿1都单 取 水層 。以10.毫此 之2當 量 氪氧 化鈉洗滌經合 併之醋酸 S& 層。 液雅:以硫酸 鈉予以 乾 燥》 且骷醚1 S&覉 真空移除 9 以 獲得 1 68毫克外 消-旋離 鈦之白色固S。將3毫升異丙基酵加至固铿產物中之後, (請先閣讀背面之注意事項再填"本頁) 13.〜 甲 4(210X297 公餐) 219983 經 濟 部 中 採 準 局 印 製 A6 B6 結晶形成。於蒸汽浴上藉加執八 下洛加至含1〇 〇毫克c i當发容解結晶。將該溶液於咒°C 之溶液中。伴隨攬拌3 於異㈣醇中) 。於挽拌4小特後過滅現却。於^分鐘後沉澉物形成 真空乾燥可獲得239毫克之白再以異丙基酵洗滌固體。 熔點:17 5。~ 1 7 7 X: 色固體’其具下述性質: 〔a〕D:=0<06〇c 甲醇) 本發明之塩類在治療病人時可 其受益。前述病人包括位库 藉ίΗΤΐΑ接受器催動劑使 ., 、抑黉、老年性政2 疾涡,如肥胖、酒精中毒 注痴呆及消耗性 a抽炫。 本發明化合物通常以製嚴β 果組合物形式投洫、 製#技螫中衆知之方法t 〜权一。孩組合物以 充。因此,本發明才q 2 :一〜正~丙基)胺基〜6〜脸基後1一 ;L 乂。含4 ~ -四氩笨幷〔c,d〕吲哚馬尿取迄迷同至少一二’ 5 格赋形劑之製梁驵合物。 製梁合 第境本發明製喿組合物時,馬尿酸塩 ,.„ 巾興賦形劑混a 濟K形㈣释爽巴被於可為繆囊、小蔡囊: 器形式之载剤中。當以騃形制充作稀释劑時,丨可.、他容 、半阁禮或液體材料,其扮演活性成分之媒劑、、载 货。因此,製祭驵合物可為錠劑、丸劑、耠―' t ^ 4口含片、 小弗囊、扁囊劑、杯1劑、懸浮劑、乳劑、溶 愛 令欲·、糖漿、卞 霧劑“1體或於液體介货中)、含例如活杜化合物重量達 瓜%之梁青、軟及硬㈣料、㈣、溶液 菌包裝粉束等螌式。 … 甲 4 (210X 297 公;^ (請先閲讀背面之注意事項再填寫本頁) *故· .線· 219933 經 濟 部 中 央 揉 準 局 印 B6 五、發明說a;];丨玉 適合賦形劑之一些货灼包括乳糖、葡萄糖、魚糖、山梁 醇木蜜醇、殿粉、金合歡修、填敗辦、餐於7醚媒、黄蓍 修、明膠、矽酸鈣、微晶織維素、聚I #基毗咯烷酮、纖 維素、水、糖漿及甲基纖維索。調配物可另外包括潤滑劑 ’如滑石、硬脂酸鎂、你酮油、或碳物油、滠澗劑、轧化 劑及懸洋劑;防腐劑,如甲暴—及丙基羥基策甲酸塩;甜 味劑夫芳杳劑。水發明組合物玎採用技發中已知步驟調配 於投與病人後提供活性成分快速、持續或延後释出。 組合物最好調配成罝一劑f蛩式,以游離城,亦卽游離 4~(二—主—丙基)桉基~6~胺基#基一1,3,4 ,5 ~四氬笨幷〔c ,d j吲哚為基準。每一劑量含約 〇。〇1毫兔至約5〇毫克,以含約Od毫克至約25毫克為 更常見。“ i 一劑量蛩式”—詞係 艰"*无作人類及其他 哨乳類單一劑爹之生理分散單位,每—_ ^ 早但含經計舁可產 生所故治療效果之預先測定童之活性啦防 _ 力贤,連同適合之制 票賦形劑。吾人應了解:赏際投與化A 表 〇物之量與投 將由箐师視相關之狀況如待處理條体 c 興效平 所'選投與这·力fi 齡、體-重、病人個別反展、病人症彡 ' .仏、年 证收又嚴重度来决6 因此上述削量範圍絶不以限制本發 决疋,而 软β範團為目的Λ 於下述配方貫例中,“馬尿醆诈”
Λ 〜詞用以;^I 化合物。該等賞例僅供説明用, 日料本發明 双絶不以限制 爲目的。 W本發明範圍 配方1 使用下述珉分製備硬明擊繆囊: …一...........................'......................裏..............................tT…:-........................線 (請先閱讀背面之注意事項再填寫本頁~
甲 4(21〇Χ 297公寿) 219933 A 6 B6 五、發明説明 馬尿酸塩 澱粉粉末 澱粉可流動粉末 C预明繆化搌粉) 石夕酮液r 35〇厘尖) j:c毫克/疹囊〕 40.0 220.0 混合上述成分以33 5毫克量填 74.20.8 充入硬明膠修囊中 配方2----£, 提供另一嵇製備硬明膠膠香士. 叢艾可法,如下: 量c毫克/綮囊〕 馬尿醭塩 殿粉 澱粉可流動粉末 C預明疹化澉粉〕 矽酮液(350厘先) 0.16 178.3 51.0 0.54 經 濟 部 中 搮 準 局 印 將澉耠以馬尿酸塩水溶液予以顆粒化。隔夜乾燥顆粒。 然後將顆粒通過20.號篩,再徹底地與·嚴粉可流動粉末及先 前混合之矽酮混合再通過· 10‘號篩,隨後調配物以23〇毫克 量填充入硬明繆繆囊中 —Sf 方 3 使用下述成分製備錠劑配*方: ......................................................^..............................訂..............................線 {請先閱讀tt面之注意事項再填寫本頁) 甲 4(210X 297 公簷) 16. **- 219933 A 6 B6 五、發明説明1 量C毫克/较:劑) 馬尿酸迄 40.0 微晶纖維素 251.7 膠態矽石二氣化物 4.5 硬脂酸 2.3 硬脂歃鎂 1 · 5 掺合組分且壓製成每一粒重量爲30 0毫克之錠劑。 配方4 使用下述組分製備錠劑配方: 量C毫克/较:劑) 馬展酸塩 0.16 殿粉 104.84 微晶纖維素 35.0 裝G _基毗咯烷酬 C ίο. %水溶液) 4 0 羧甲基鈉澱粉 4.5 硬脂酸鎂 0.5 滑石 1.0 使滅:耠及織維素通過20.號篩, 1且徹底地混合 {請先閔讀背面之注意事項再填寫本頁 •^. .訂· •線· 經濟部中央採準局印裝 基毗洛烷酮溶液與所產生粉末混合之後通過4號篩。於50. —60. Ό下乾燥顆粒,再通過16·號篩。將先前通過30.號篩之 羧甲基鈉·殿粉、硬脂酸鎂及滑石加入顆粒中,再予以混合 。隨後於壓錠梭器上壓製混合物以產生每一粒重量為1 50 毫克之鼓劑。 甲 4(210X 297公尨) -17.- 219933 A6 B6 五、發明説明丨6> : 另一製備方法爲使馬尿酸塩、澱粉及纖維素通過20.號篩 ,且徹底地混合。繼之將聚已烯基吡咯烷酮溶液與所產生 粉末混合之後通過4號篩。於50. - 60l °C下將顆粒乾燥,再 通過16.號篩。將先前通過30.號篩之羧甲基鈉澱粉、硬脂酸 鎂及滑石加入顆粒中再予以混合。然後於壓錠機器上墼製 混合物以農生每一粒重爹爲15 0毫克之鏡:劑。 (請先聞讀背面之注意事項再填寫本頁 •訂· ." 經濟部中央橾準局印製 甲 4(210X 297 公餐) 18.-
Claims (1)
- 3 丙基)tr 广 - 〜基_ 6 ~桉基羰暴 219933 六'申琦專利範® r 4 -(二n基)胺基υ 4 , 5 ~四氩笨丹〔c 火基 ,d〕吲哚爲尿醆作。 2.根捉申請專利範園第i項 ^ 化合物,其t質上务(4S )~A — ( — — 3 ,4 , 5-四氬笨并— 1梘Μ由β * , k C ,d〕叫I今馬來發洛。 3. 根披申叫專别苑固箪】巧 )__4— _ -" 疋化合物,其贅質上爲C4R 3 4 C I—丙基)桉募-6 ~ 基辕蟇—1, 四也策并L C,…嘴馬尿… 4. 一種用為5HT1A俏# 13尿蹤塩 專利範圍第i、2 /之#學組合物,其包含根據申請 蔡上合格赋形劑、稀3釋化合物連同-種或多種典製 5根Μ由> Φ 稀釋劑或戴劑。 5-根據申請專利範 C - 禾1λ2成3孕 之 4一 (_ -主—丙基 ^ )心不―6〜桉基羰基〜1 3 , 4 , 5 -四虱笨井〔e tTfTW ,01 J吲啥馬展酼塩, 為5 ΗΤί A催動劑。 係用 6. 根據申'請專 (二n/ ®第1 、2或3項之4 — , .^ 土0桉基—6~·胺基羰基一1,3 ,4, 5 —四息策丹〔 慮劑。 c ,d h引吟馬尿爲抗焦 7. 根據申請專^ (二— 範圍第1、 2或3項之4 — ~~丙基〕桉基—6 —胺基羰基一;l,3,4, 5 ~四氩笨拜〔 抑费。 ^ ,d j吲哚馬尿駿塩,係用以治療人類 & —狡褽備根披 或 (請先閲讀背面之注意事項再填寫本頁) -裝· 經濟部中央標準局印裝 2 μ專利範圍第 f 4(210X297 公;^3 19.- 219933 at B7 C7 __D7_ 六、申請專利範® 結晶塑4 —(二-正一丙基〕胺基一1 , 3 ,4 ,5 —四 采幷〔c ,d〕。引嗓馬尿酸迄之方法,该方法包含⑻ 合併4 ~ C二~—丙基〕一胺基-~1 ,3 ,4 ,5 — 四氮笨并〔c , d J吲哚及馬尿酸,以及⑹從溶液中結 晶该馬尿酸塩以提供該結晶馬尿酸塩。 9. 根據申請專利範圍第8項之方法,其中該溶液含異丙基 醢併合至少約10.容雅百分率之水。 10. 根拔申請專利苑園第8項之方法,其中该結晶馬尿醆塩 係溶於包含異丙基醇及至少約15.容積百分率水之第二溶 劑中,且隨後從该第二溶劑中結晶4 — C二-正一丙基 )胺:— 1 ,3 ,4 , 5 —四 |L 笨并〔c ,d J °引 σ朵馬 尿酸塩以提供再結晶馬尿酸塩與母液。 11. 根據申請專利貌圍笫10.項之方法,其中該母液可再循環 充作吞第二溶劑。 12根據申請專利範圍第8項之方法,其中該.結晶馬尿駿塩 係溶於a含G醇之弟二溶劑中,隨後從該弟二溶劑中再 結晶出4 一 f二一!一丙基-)胺基一1 ,3 , 4 ,5- 四乳采幷〔c ,d J吲吟馬尿酸迄。 (請先閲請背面之注意事項再填寫本頁) •装· •綠. 經濟部中央標準局印裝 甲4C210X 297/二、犮) ^19^33 第七九一〇五二五八號專利申謫案 中立補夺銳明害(82年3月) LY228729及LY225303化合物與5-HT\a受體親和力之比較 S__^ 依下述之方法於5-HT1A受傾之檷準放射性配位體結合分析試驗評 估* Μ測定LY228729化合物(游離碱)對5-HT1Ag體之親和力是否受該 化合物之馬尿酸鹽影響。LY2287 29化合物(游離碱)及其禺尿酸鹽 (LY225 303)之競爭曲線基本上係兩相重叠的(請參考附圖)。228729之 ICB〇值(即抑制50%结合所痛之濃度)係0.20nM ,而225303為0.19nM 。是以,结論是,LY228729及其馬尿酸SiaY225303)與5-叮^受«親 和力間無差異。 £___ 使用 Taylor et al (J. Pharmacol, Exp, Ther, 236:118-125, 1986>所述结合分析試驗之修飾法测定化合物與中榧神纆5-HT1A受體 之親和力。由雄性Sprague-Dawley老鼠(150-250克)準備结合分析試 驗用薄膜。截去頭部以殺死老鼠•迅速冷凍其腦部,解剖取其海馬角 。可在當日從海馬角準備薄膜,或將海馬角冷凍(-70t:)儲存至準備 之日使用。使用16(^0131'1'!55111«丨261'(設定於65,15秒)*使在40容 稹量之冰鎮Tris-HCl嫒衝液(50·Μ,22C時PH7.4)中之姐嫌勻漿化· 以準備薄膜•於39800xg離心勻10分鐘。而後將所得小顆粒再》浮於 相同媛衝液中。另行重覆離心及再懋浮步驟三次*以冲洗該薄膜。在 第二次及第三次冲洗之間,在371下培養懸浮薄膜ΐϋ分鐘,Μ利内源 性配位物之移除。將最後之小顆粒再懸浮於67bM Tris-HCl (ΡΗ7.4) 中,使濃度變為2奄克姐嫌原始濕重/200微升。冷凍儲存該匀漿(-7010 )至结合分析試驗之日。每一结合分析試驗試管終體積為800微 升,含下列物質:Tris-HCU5〇BM),甲丙苄胺(10w M), CaCl2(3BM),[3H]8-0H-DPAT(1.0nM),受試藥物之遘當稀釋液及相當 sh\0019.g 219933 於2奄克原始姐嫌濕重之薄膜懸浮液•最終pH為7.4 。於37 TO下培養 分析試管分鐘,而後MGF/B過濾器(預先K0.5 %聚伸乙亞胺處理 過)快速遇«其内容物,接著*以1毫升冰縝媛衝液冲洗四次。使用 液態閃爍光譜儀定量該濾膜上留滯之放射線活性· [3H]8-0H-DPAT與 5-HT1A位置之特異性结合係定義為其在10« Μ 5-HT存在時與不存在時 结合之差值。 MlCso值(抑制50%结合作用所蒲之濃度)表示化合物與5-ΗΤ1Α受體 之親和力。該值係Κ非線性回歸法(SYSTAT, SYSTAT. Inc. Evanston, IL) ·由競爭曲線測定。該曲線上之每一點係單一試驗之 三次測量之平均值土 SEM值。 2 sh\0019.g 219933 Η^Ν 228729(.)2./x>\/\ 特異性結合部份 C #狩矣性結合=1 X 10_5M5 — HT) > ρ ρ Ο Ο 〇 t-* * η* co **<ι i—i -53s·) ον, -1P5-10 -9.5 -9 -8.5--7.5 -7 -6.5 -6 丨 5.5 -5 -4.5 耸烊命〔嘸赛〕· Μ22S7S 0 wo 2S303 0.19 【%】8-0H-DPAT^'%^^.¾ 滁命炒-- IC5°(l)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48518590A | 1990-02-26 | 1990-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW219933B true TW219933B (zh) | 1994-02-01 |
Family
ID=23927224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW079105258A TW219933B (zh) | 1990-02-26 | 1990-06-26 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5397799A (zh) |
| EP (1) | EP0444852B1 (zh) |
| JP (1) | JP3157007B2 (zh) |
| KR (1) | KR100208114B1 (zh) |
| CN (1) | CN1027503C (zh) |
| AT (1) | ATE126506T1 (zh) |
| AU (1) | AU629453B2 (zh) |
| BR (1) | BR9100767A (zh) |
| CA (1) | CA2037099C (zh) |
| CY (1) | CY1887A (zh) |
| DE (1) | DE69112099T2 (zh) |
| DK (1) | DK0444852T3 (zh) |
| ES (1) | ES2077796T3 (zh) |
| FI (1) | FI95464C (zh) |
| GR (1) | GR3017940T3 (zh) |
| HK (1) | HK175495A (zh) |
| HU (1) | HU217118B (zh) |
| IE (1) | IE67801B1 (zh) |
| IL (1) | IL97306A (zh) |
| LV (1) | LV10251B (zh) |
| NO (1) | NO174149C (zh) |
| NZ (1) | NZ237181A (zh) |
| PT (1) | PT96852B (zh) |
| RU (2) | RU2034837C1 (zh) |
| SG (1) | SG69975A1 (zh) |
| TW (1) | TW219933B (zh) |
| YU (1) | YU47594B (zh) |
| ZA (1) | ZA911258B (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL97309A (en) * | 1990-02-26 | 1996-11-14 | Lilly Co Eli | Intermediates for hexahydrobenz Úcd¾ indoles and process for the preparation of pure enantiomers thereof |
| US5302612A (en) * | 1990-02-26 | 1994-04-12 | Eli Lilly And Company | 6-substituted-hexahydrobenz[cd]indoles |
| IL97308A (en) * | 1990-02-26 | 1996-10-31 | Lilly Co Eli | 6-Substituted-hexahydrobenz (cd) indoles process for their preparation and pharmaceutical compositions containing them |
| US5656653A (en) * | 1991-03-28 | 1997-08-12 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles |
| US5364856A (en) * | 1991-03-28 | 1994-11-15 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles |
| TW248556B (zh) * | 1993-01-18 | 1995-06-01 | Takeda Pharm Industry Co | |
| UA53205C2 (en) * | 2002-04-03 | 2006-06-15 | Pharmatech Close Joint Stock C | Antidepressant formulation and method for its manufacture |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| EP3698794A1 (en) | 2009-11-06 | 2020-08-26 | Aerpio Therapeutics, Inc. | Compositions and methods for treating colitis |
| EP2717870B1 (en) | 2011-06-06 | 2017-09-27 | Akebia Therapeutics Inc. | Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer |
| NO2686520T3 (zh) | 2011-06-06 | 2018-03-17 | ||
| SG10201910773VA (en) | 2013-06-13 | 2020-01-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| EP3790863A1 (en) | 2018-05-09 | 2021-03-17 | Akebia Therapeutics Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110339A (en) * | 1977-11-25 | 1978-08-29 | Eli Lilly And Company | 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole |
| US4576959A (en) * | 1984-02-06 | 1986-03-18 | Eli Lilly And Company | 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles |
| US4745126A (en) * | 1987-03-12 | 1988-05-17 | Eli Lilly And Company | Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides |
| DE3809155A1 (de) * | 1988-03-18 | 1989-09-28 | Bayer Ag | 1,3,4,5-tetrahydrobenz-(c,d)-indole |
| US5204340A (en) * | 1989-04-11 | 1993-04-20 | Eli Lilly And Company | Tetrahydrobenz(c,d)indole serotonin agonists |
| US5229409A (en) * | 1990-08-15 | 1993-07-20 | Eli Lilly And Company | 6-substituted-tetrahydrobenz[cd]indoles |
-
1990
- 1990-06-26 TW TW079105258A patent/TW219933B/zh active
-
1991
- 1991-02-20 ZA ZA911258A patent/ZA911258B/xx unknown
- 1991-02-20 IL IL9730691A patent/IL97306A/en not_active IP Right Cessation
- 1991-02-21 NZ NZ237181A patent/NZ237181A/en unknown
- 1991-02-22 JP JP05064391A patent/JP3157007B2/ja not_active Expired - Fee Related
- 1991-02-22 PT PT96852A patent/PT96852B/pt not_active IP Right Cessation
- 1991-02-25 AU AU71971/91A patent/AU629453B2/en not_active Ceased
- 1991-02-25 RU SU914894699A patent/RU2034837C1/ru not_active IP Right Cessation
- 1991-02-25 FI FI910895A patent/FI95464C/fi active
- 1991-02-25 NO NO910735A patent/NO174149C/no unknown
- 1991-02-25 YU YU32791A patent/YU47594B/sh unknown
- 1991-02-25 KR KR1019910003029A patent/KR100208114B1/ko not_active Expired - Fee Related
- 1991-02-25 HU HU91629A patent/HU217118B/hu unknown
- 1991-02-25 IE IE62591A patent/IE67801B1/en not_active IP Right Cessation
- 1991-02-26 DE DE69112099T patent/DE69112099T2/de not_active Expired - Fee Related
- 1991-02-26 EP EP91301501A patent/EP0444852B1/en not_active Expired - Lifetime
- 1991-02-26 CN CN91101296A patent/CN1027503C/zh not_active Expired - Fee Related
- 1991-02-26 DK DK91301501.2T patent/DK0444852T3/da active
- 1991-02-26 BR BR919100767A patent/BR9100767A/pt not_active Application Discontinuation
- 1991-02-26 CA CA002037099A patent/CA2037099C/en not_active Expired - Fee Related
- 1991-02-26 ES ES91301501T patent/ES2077796T3/es not_active Expired - Lifetime
- 1991-02-26 SG SG1996007257A patent/SG69975A1/en unknown
- 1991-02-26 AT AT91301501T patent/ATE126506T1/de not_active IP Right Cessation
-
1992
- 1992-12-03 RU RU9292004575A patent/RU2083561C1/ru not_active IP Right Cessation
-
1993
- 1993-05-19 US US08/064,539 patent/US5397799A/en not_active Expired - Lifetime
- 1993-06-08 LV LVP-93-509A patent/LV10251B/xx unknown
-
1995
- 1995-11-01 GR GR950403048T patent/GR3017940T3/el unknown
- 1995-11-16 HK HK175495A patent/HK175495A/en not_active IP Right Cessation
-
1996
- 1996-04-05 CY CY188796A patent/CY1887A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW219933B (zh) | ||
| ES2920681T3 (es) | Compuestos | |
| TW538039B (en) | Neutral S-omeprazole in a form or b form, process for preparing the same, and pharmaceutical composition comprising the same | |
| CN106163516B (zh) | 异吲哚啉组合物和治疗神经变性疾病的方法 | |
| JP2821233B2 (ja) | 脳乏血の予防ならびに治療におけるアダマンタン誘導体 | |
| JP5584626B2 (ja) | 2−アルキルアミノ−3−(アリールスルホニル)−シクロアルキル[e又はd]ピラゾロ[1,5−a]ピリミジン−セロトニン5−HT6受容体アンタゴニスト、その調製の方法及び使用 | |
| TW201002317A (en) | Cathepsin C inhibitors | |
| IL299125B1 (en) | Substituted piperidine compound and application thereof | |
| CN110325535A (zh) | 经哌啶、吗啉或哌嗪取代的作为oga抑制剂的[1,2,4]-三唑[1,5-a]-嘧啶基衍生物 | |
| MX2008011553A (es) | Formulacion de polialcohol de ciclohexano para el tratamiento de transtornos de agregacion de proteinas. | |
| KR20000048518A (ko) | 정신병 치료를 위한 조합 요법 | |
| US20110189306A1 (en) | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | |
| TW200823232A (en) | Metastin derivatives and use thereof | |
| JP6166899B2 (ja) | ダウン症患者の認識機能障害を治療するための組成物及び方法 | |
| TW201221128A (en) | Crystalline forms of a factor Xa inhibitor | |
| KR20150140386A (ko) | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 | |
| CN109310694A (zh) | 治疗儿科癌症的方法 | |
| TW314468B (zh) | ||
| JP6384923B2 (ja) | N−(3−(4−(3−(ジイソブチルアミノ)プロピル)ピペラジン−1−イル)プロピル)−1H−ベンゾ[d]イミダゾール−2−アミンの硫酸塩、その製造、及びその使用 | |
| CN115916187A (zh) | 治疗蛋白病相关的游荡的方法 | |
| Mukasa et al. | Activation of caspase-3 apoptotic pathways in skeletal muscle fibers in laminin α2-deficient mice | |
| Lindvall et al. | Infantile systemic hyalinosis: case report and review of the literature | |
| TW200902537A (en) | Glucocorticoid receptor modulator and methods of use | |
| TW200940543A (en) | Maleate, besylate and L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine | |
| CN109790180A (zh) | 毒蕈碱乙酰胆碱受体激动剂的结晶多晶型物 |